Exenatide ER

Bydureon · Bydureon BCise

GLP-1 Receptor Agonist GLP-1 SubQ FDA/EMA Label

Half-life

7 days

Time to Peak

14 days

Steady State

~35 days

Dose Range

2–2 mg

Frequency

Weekly

Overview

Once-weekly injectable extended-release GLP-1 receptor agonist for type 2 diabetes. Microsphere formulation takes 6-7 weeks to reach steady-state therapeutic levels.

Mechanism of Action

Same exenatide molecule in poly(D,L-lactide-co-glycolide) microsphere sustained-release formulation. Biphasic release: initial burst then prolonged depot release over weeks.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Subcutaneous (SubQ)	2–2 mg	7 days	14 days	Weekly

Storage & Handling

2-8C — Refrigerate. Can store at room temp (up to 25C) for up to 4 weeks. Do not freeze.

Used in Regimens

Exenatide ER is not currently part of any catalog regimen.

Data Sources

FDA Label Bydureon BCise FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Exenatide ER with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.